Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population by unknown
Brief Definitive Report 
REGRESSION  AND  INHIBITION  OF  SARCOMA  GROWTH 
BY  INTERFERENCE 
WITH  A  RADIOSENSITIVE  T-CELL  POPULATION* 
BY K. E. HELLSTROM, I. HELLSTR(~M, J. A. KANT,~ AND J. O. TAMERIUS§ 
From the Division of Tumor Immunology, Fred Hutchinson Cancer Research Center, Seattle, Washington 
98104, and the Departments of Pathology, Microbiology, and Immunology, University of Washington School 
of Medicine, Seattle, Washington 98195 
Suppressor cells facilitate the growth of neoplasms that have tumor-specific trans- 
plantation  antigens  (TSTA)  (1-7).  In  in  vivo neutralization  tests,  suppressor cells, 
upon exposure to TSTA, enhance the growth ofsyngeneic sarcomas in both untreated 
and preimmunized hosts (7). These suppressor cells are recruited from a radiosensitive 
T-cell  population  which  is  present  in  the  spleens  of both  unsensitized  and  tumor- 
bearing  animals.  In  another  system,  the  cells  facilitating tumor growth  have been 
shown to have surface markers that are characteristic of suppressor T  cells and that 
are coded for by the I-J subregion of the H-2 complex (6).  Despite the presence of 
suppressor activity, anti-tumor immunity can regularly be demonstrated both in vitro 
and in vivo in mice bearing small syngeneic tumors (8).  Furthermore, this immunity, 
once generated, is fairly radioresistant  (9). 
Since radiosensitive suppressor cells facilitate tumor growth in vivo, since there is 
an anti-tumor immune response despite this suppression in tumor-bearers, and, since 
the  immune  response  is  fairly  radioresistant,  we  hypothesized  that  whole  body 
irradiation of mice with small tumors might preferentially interfere with the genera- 
tion of suppressor cell activity, thus allowing a stronger anti-tumor immune response 
and consequent retarded tumor growth. 
We show in this report that the growth of immunogenic tumors can be inhibited 
and even complete regressions achieved by whole body irradiation.  Furthermore, we 
demonstrate that the essential effect of the irradiation is not on the tumor tissue itself, 
but  most likely on host  T  cells.  These observations suggest  that  in  addition  to the 
usual rationale for therapeutic uses of irradiation in cancer, treatment protocols that 
take into account an individual's suppressor mechanism may merit consideration in 
the future. 
Materials and Methods 
Experimental Outline.  Mice were inoculated subcutaneously into both flanks with tumor cells, 
giving two potential tumor "sites" per mouse. The mice were randomized into various treatment 
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groups (see Results); 6-8 days later, one group of mice was left untreated, and the other groups 
were given 400 rads of whole body irradiation. One group of irradiated mice was not further 
treated, whereas other groups were inoculated intravenously with spleen cells from nonsensi- 
tized, 6-8-wk-old BALB/c females. These spleen cells were either unfractionated, or they were 
enriched for, or deprived of T  cells as described below. 
The mice were examined twice weekly for tumor growth. Two perpendicular tumor diameters 
were measured. Mean tumor diameters in millimeters (X  ±  SE) for all sites per group were 
calculated, with negative sites being counted as 0.  Statistical significance was estimated by 
Student's t  test. All mice were ear-tagged. The treatment  of the mice was unknown  to the 
person scoring the animals. 
Mice and Tumors.  BALB/c mice were bred by brother/sister mating, and were regularly 
checked for their ability to accept intrastrain skin grafts. 6-8-wk-old females were used. 
Two methylcholanthrene-induced sarcomas, 1315 and  1425 (10), were maintained by serial 
transplantation for 10-15 passages before use. Both possess strong individually unique TSTA, 
weak common tumor-associated antigens (10), and murine leukemia virus-associated antigens 
(11). 
Tumor cell suspensions were prepared from fragments of healthy tissue by trypsinization 
(0.025% trypsin and 5 mM EDTA for 10 min), and they were washed in Waymouth's medium 
(Grand Island Biological Co., Grand Island, N. Y.). The mice were inoculated subcutaneously 
with 10  e viable tumor cells into each flank. 
Irradiation Procedures.  Mice were given a sublethal dose (400 rads) of whole body irradiation 
from two opposing cobalt-60 sources. 
Preparation of T-Cell-Enricked Spleen Cell Suspensions.  Nylon wool columns to which non-T cells 
would bind preferentially were utilized according to Julius et al. (12).  After column passage, 
88-94% of the nonadherent cells were killed by a mouse anti-Thy-1.2 serum and complement, 
compared to 28-39% of the unfractionated spleen cells. 
Preparation and  Testing of a  Goat Anti-T-Cell  Serum.  A  goat  was  immunized  three  times 
subcutaneously with rat brain in complete Freund's adjuvant  (Difco Laboratories, Detroit, 
Mich.) to obtain antibodies cross-rcacting to mouse T lymphocytes (13). The antiserum, which 
was heat-inactivated (56°C,  30 min) and exhaustively absorbed with BALB/c bone marrow 
cells, was tested on various BALB/c lymphoid cells for complement-dependent cytotoxicity, 
using a nlCr release assay. After the last absorption, bone marrow cells were not affected by the 
serum plus complement at all, whereas 90% of thymus cells and 25-35% of spleen cells were 
killed at  a  serum dilution of 1:50.  Spleen cells incubated with  1:50  diluted antiserum and 
complement retained full ability to synthesize DNA upon exposure to lipopolysaccharide,  while 
their ability to  proliferate upon  exposure to  phytohemagglutinin was  lost. This  antiserum 
abolished the in vitro cytotoxic activity of aUoimmune lymphocytes (14), as well as the in vivo 
reactivity of tumor-immune lymphocytes in (Winn) neutralization assays (unpublished obser- 
vations). 
To prepare T-deprived spleen cells for adoptive transfer, 2.5  ×  107 cells/ml were suspended 
in Waymouth's medium, and an equal volume of 1:7 diluted goat anti-T serum was added. 
The mixture was incubated for 2 h at 4°C, after which pretested (nontoxic) rabbit complement 
(from 10-wk-old San Juan rabbits) was added to a final dilution of 1:20 and the mixtures were 
incubated at 37°C for 1 h. The cells were then washed twice, diluted in Waymouth's medium, 
and counted. 
Results 
Two preliminary tests showed that whole body irradiation of mice carrying sarcoma 
1315 decreased tumor growth, provided that the irradiation was done 6-8 days after 
tumor  transplantation  (when  the  tumor just  started  appearing);  no  such  effect  of 
radiation  was  seen  when  it  was  given  10  or  more  days  after  transplantation.  We 
decided, therefore, to start our treatments 6-8 days after tumor transplantation. 
Three experiments were performed. In the first,  10  s cells from sarcoma  1315 were 
transplanted  subcutaneously  into each  flank of syngeneic BALB/c  females.  8  days 
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TABLE I 
Inhibition of 1315 Sarcoma Growth by Whole Body Irradiation (400 fads) of Mice Bearing Small Tumors 
Group  Treatment of mice* 
Tumor size at different time points after inoculation X  4- SE (20 
sites/group) 
Number of tu- 
mor sites with 
complete regres- 
sion/total 
8 days  14 days  21 days  27 days  36 days  60 days 
A  None  0.7 -t- 0.2  4.1  :it: 0.5  7.0 -4- 0.9  11.3  4-  1.3  13.5 4-  1.4  0/20 
B  400 rads  0.94-0.1  2.5:1:0.2  3.2=1:0.7  3.64-1.2  6.3:t:2.1  7/20~ 
C  400 rath  followed by spleen  0,9 4- 0.1  3.6 4- 0.4  5.6 4- 0.4  9.2 4- 0.5  >15.0  0/20 
cells, i.v. 
Statistical  significance  of dif-  A-B  NS  0.01  0.01  0.001  0.02  0.004 
ferences between groups 
(P <)§  B-C  NS  0.05  0.01  0.001  0.01  0.004 
* On day 1 the mice were inoculated subcutaneously in each flank with 10  e sarcoma 1315 cells. Mice in groups B and C were irradiated on day 
8, and mice in group C were also injected intravenously with 5  ×  l0  s syngeneic spleen cells 2 h later. 
:~ In all 7 cas~, small tumors were observed to regres completely. 
§ The statistical significance of the differenceg between groups in mean tumor diameter was determined by Student's t tests; significance in 
frequenc~ of tumor regression was determined from Fischer Table. NS, not significant; X, mean. 
A was untreated, group B was given 400 rads of whole body irradiation, and group C 
was  given 400 rads of whole body irradiation,  followed in  2  h  by the intravenous 
injection  of 5  ×  l0  s  viable  lymphoid  ceils  from  the  spleens  of normal  BALB/c 
females. Tumor growth was significantly inhibited in the irradiated mice that received 
no spleen cells (group B). After an initial, weak inhibition seen in the irradiated group 
that received spleen cells (group C), tumor growth in this group was essentially the 
same as in the untreated mice (group A). Most remarkably, complete regression of 
tumors that had first grown to 2-4-mm diameters, was seen in 7 of 20 sites in group 
B; three mice had regression of their tumors on both sides, and remained tumor-free 
more than 3 mo later, by which time all the 20 control mice (groups A and C) and 
the remaining 7 mice in group B had died from tumor. 
The lymphoid cells facilitating tumor growth upon adoptive transfer to irradiated 
mice were T  cells. As shown in Table II, the growth of sarcoma 1315 was significantly 
inhibited by whole body irradiation  (group B), and four complete regressions were 
observed. The therapeutic effect of  the irradiation was counteracted by the intravenous 
injection  of 2  ×  10  7  unfractionated  spleen  cells  (group  C),  thus  confirming our 
observations in Table I. The tumors of the irradiated mice passively receiving T-cell- 
enriched spleen cells (group D) grew like the tumors in the untreated controls (group 
A), whereas the tumors of the irradiated mice receiving 2  ×  10  7 T-depleted spleen 
cells  (group E)  grew much more slowly, and six of these regressed completely (and 
permanently). 
In a third experiment, we also showed a therapeutic effect of irradiation on another 
sarcoma,  1425,  which  had  been  independently  induced  by  methylcholanthrene. 
However, the effect of irradiation was less pronounced than with sarcoma 1315. The 
1425 tumors in the irradiated mice receiving T-deprived spleen cells were significantly 
smaller after 15 (P <  0.01) and 20 days (P <  0.001) of growth than the tumors in the 
irradiated  mice  receiving T-enriched spleen  cells,  but  this  difference disappeared 
completely by 29 days of tumor growth. 
Discussion 
We have presented evidence that tumor growth can be inhibited significantly when 802  HELLSTROM ET AL.  BRIEF  DEFINITIVE REPORT 
TABLE  II 
The Inhibition of Tumor Growth Caused  by Whole Body Irradzation of Mice Carrying Small Tumors Can 
Be Prevented  by Normal Syngeneic Spleen T Cells 
Group  Treatment of mice* 
Tumor size 6-41 days after inoculation X  2:  SE (20 sltes/group) 
Number of tumor 
sites  with complete 
regression/total 
15 days  20 days  29 days  41 days 
A  None  4.~  ±  0.3  62 2:0.6  II.9  2:0.7  [36 2:0.0  0/40 
B  400 rads day 6  29 2:0.2  2.8  2:0.9  4.5 2:1.5  75 ±  2. t  4/10:~ 
C  400  rads  day  6  +  2  x  10  ~  2.8±07  512:1.3  106 2:1.7  131  ±  I.(J  0/10 
spleen  cells,  i.v. 
I)  400 rads day 8  +  2  X  I07 T -  39 ±  0.3  6.12:[].5  10.2+06  14,6±03  (]/20 
enriched spleen  ceils,  i.v. 
E  400 rads day B  +  2  x  10v T -  2.92:0.5  2.82:0.8  5.11 ±  1.3  852:t5  6/20:~ 
deprived spleen cells,  i v. 
Statistical significance of differ- 
ence  between  groups  (P  <)§ 
A-B  0.05  0.0I  0.001  0 00[  0.002 
A-C  NS  NS  NS  NS  NS 
B  C  NS  0 02  ().02  0 05  I).05 
A  I)  NS  NS  NS  NS  NS 
A  E  005  0.01  0,001  0,0I  O~ll 
D-E  0 005  0 01  0.01  0.001  00I 
* The mice were inoculated on day  I subcutaneously in each flank  with  10  b cells  fi'om sarcoma  1315 (pIoviding 2 tumor sites per mottsc)  400 
rads of whole body  irradiation were given  on  day 6 or 8 after tumor transplantation.  Spleen cells  were int~:ulated intravenously 2 h  aft(') 
irradiation; procedures for obtaining T-enriched and T-deprived spleen cell suspensions  are described m  Material~ and Methods 
:~ In all  10 cases,  small tumors werv observed  to regress  completely 
§ See footnote to Table I 
mice carrying small, subcutaneously transplanted tumors are given 400 rads of whole 
body irradiation. Most importantly, on several occasions complete tumor regressions 
were  seen  in  irradiated  mice  carrying  1315  sarcomas.  The  cells  affected  by  the 
radiation  treatment  were most  likely lymphoid cells rather than  tumor cells, since 
intravenous injection of spleen cells from nonsensitized, syngeneic mice abolished the 
radiation effect. The responsible spleen cells were T  lymphocytes. 
These observations support the hypothesis that a population of suppressor T  cells 
exists in tumor-bearing animals where it plays an important role in facilitating the 
growth of immunogenic tumors. It also suggests that the suppressor cells, at least in 
the early phase of tumor growth  (between 6  and 8  days), are recruited from a  cell 
population which is sensitive to irradiation. At a later stage of tumor growth (10 days 
or later), a similar effect of whole body irradiation was not observed. This loss of the 
therapeutic  effect of irradiation  may be  related  to  the  eclipse  phenomenon  (15), 
and/or to the  presence of appreciable amounts of circulating tumor antigens  and 
other blocking factors (16) at that time, including those already formed by suppressor 
T  cells (17). These phenomena are both related to tumor load (18). The development 
of resistant  to  irradiation  could  also  be  due  to  the  presence of already  activated 
suppressor cells which may have become less radiosensitive than the cell population 
from  which  they were  derived  (19).  We  are  presently conducting experiments  to 
explore these possibilities. 
The therapeutic effect of irradiation was most dramatic against the 1315 sarcoma. 
Although this tumor, which we have studied extensively, does not regress normally, 
we observed about 30% permanent regressions as a result of irradiation in this study. 
Irradiation significantly retarded the growth of 1425 sarcomas, but this effect disap- 
peared  completely after 4  wk of tumor growth.  The difference between  these  two 
tumors may relate to a  difference in  their immunogenicity, since  1315  is  the more HELLSTROM El" AL.  BRIEF  DEFINITIVE REPORT  803 
immunogenic of the  two  in standard  transplantation  tests  (10).  Recently, we have 
obtained results similar to those for  1425 with another sarcoma,  1460, which is also 
less immunogenic than  1315. These observations emphasize the fact that each tumor 
is  unique,  and  that  different  modalities  may  be  required  to  achieve  the  same 
therapeutic effect. 
We believe,  nevertheless,  that  the approach  described  here,  as well  as the  use  of 
drugs such as cyclophosphamide instead of irradiation to preferentially interfere with 
suppressor cell activity while leaving the effector cell activities intact  (20), can have 
general applicability to treating tumors of the mouse. An approach aimed at interfer- 
ence with suppressor cell activity may also have value as an adjunct to human cancer 
therapy. 
We are anxious to point out, however, that we have not excluded that the radiation 
effect is due to the elimination of radiosensitive  cells responsible for immunostimula- 
tion  (21), and perhaps contributing to a  stromal  reaction contributing to the size of 
tumor nodules. This explanation is less likely, however, since our tumors grow well in 
nonimmunized BALB/c mice receiving 400 rads, and since permanent regression was 
seen in  17 of 50 tumor sites. 
Summary 
BALB/c  mice were  inoculated  subcutaneously  with  106 cells  from either  of two 
syngeneic sarcomas  1315  and  1425.  6-8 days later,  the  mice were randomized  into 
groups  which  were  left  untreated  or  given  400  rads  of whole  body  irradiation. 
Irradiation  significantly retarded  the growth of both sarcomas, and complete regres- 
sions were seen of ~  30% of the small, established  1315 tumors. The anti-tumor effect 
of irradiation  was  abolished  if the  irradiated  mice  were  inoculated  with  a  T-cell- 
enriched  (but  not  with  a  T-cell-deprived)  suspension  of syngeneic spleen  cells,  sug- 
gesting  that  the  irradiation  inhibited  tumor  growth  by  affecting  a  radiosensitive 
population of host suppressor T  cells. 
We thank Linda Katzenberger and Craig Bailey for their excellent technical assistance. 
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